CBD–Terpene Sleep Trial: The Average Effect Was Smaller Than the Best-Responder Result

A CBD–terpene trial found a small average change in wearable-estimated sleep stages, while the largest reported improvements occurred in selected responders. Those responder figures should not be presented as the expected benefit for everyone with insomnia.

A combined formulation and incomplete datasets

The study used 300 mg CBD with eight terpenes, each at 1 mg, in a placebo-controlled crossover design. Treatment periods lasted four weeks, separated by washout. Although 125 participants entered the study, the final complete-data analysis included 56.

The intervention was not pure CBD. Without separate CBD-only and terpene-only arms, the experiment cannot identify which component caused a change or demonstrate a synergistic interaction.

The mean effect was modest

The reported average increase in the combined share of slow-wave and REM sleep was approximately 1.3 percentage points compared with placebo. Total sleep time, resting heart rate and heart-rate variability did not show significant treatment effects.

More substantial estimates appeared in subgroups and selected high responders. A best-responder average is conditional on selection and cannot replace the overall treatment estimate when discussing likely benefit.

The device did not measure laboratory sleep stages directly

Sleep was assessed using a wrist-worn tracking device rather than polysomnography. The authors explicitly questioned the device’s sleep-staging accuracy and called for confirmation in a sleep laboratory.

Loss of complete datasets, the modest overall result and subgroup analyses limit precision and generalizability. The study provides a preliminary signal for a specific combination, not proof of broad insomnia efficacy or an expectation of dozens of additional restorative-sleep minutes for every user.

Related: Interpreting clinical cannabinoid outcomes.

Primary research

Effects of a cannabidiol/terpene formulation on sleep in individuals with insomnia: a double-blind, placebo-controlled, randomized, crossover study. Journal of Clinical Sleep Medicine : JCSM : Official Publication of the American Academy of Sleep Medicine (2025).

Spread the love


The National Black Lawyers

top 40 lawyers

civil trial law

Lawyers of Distinction

Loading...

Recent Blog Articles

What Skin Tags Along an Abrasion Can Show About Direction

Knight’s Forensic Pathology explains how superficial skin fragments can help interpret a scraping injury.

Spread the love

Read Article: What Skin Tags Along an Abrasion Can Show About Direction

Why Stomach Contents Provide an Uncertain Timeline After Death

Knight’s Forensic Pathology explains how meal composition and stress complicate estimates based on stomach contents.

Spread the love

Read Article: Why Stomach Contents Provide an Uncertain Timeline After Death

What Did the Confirmatory Phase 3 MDMA-Assisted Therapy Trial Add?

The MAPP2 trial replicated symptom and functional improvements in a more ethnoracially diverse PTSD sample. It also left important questions about blinding, long-term outcomes, exclusions, and sponsor involvement.

Spread the love

Read Article: What Did the Confirmatory Phase 3 MDMA-Assisted Therapy Trial Add?

Speak with an expert today!

Contact the offices of Okorie Okorocha for professional and reliable advice which you can trust.

Call (424) 363-3347 Contact Us